+260.8%
TXN vs MRNA
+554.4%
-293.6%
-33.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +3.8% | +5.4% | -1.6% | +3.6% |
| 7D | +4.0% | -1.1% | +5.1% | +4.0% |
| 30D | -2.9% | +126.1% | -129.0% | -10.4% |
| 3M | -9.1% | +190.0% | -199.1% | -18.7% |
| 6M | +36.6% | +157.2% | -120.6% | +23.3% |
| YTD | +57.5% | +388.2% | -330.7% | +32.9% |
| 1Y | +49.5% | +467.0% | -417.5% | +23.8% |
| 3Y | +76.5% | +36.1% | +40.5% | +60.5% |
| 5Y | +62.4% | -68.0% | +130.3% | +55.0% |
| All | +260.8% | +554.4% | -293.6% | +198.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling